GALECTIN THERAPEUTICS INC - COM NEW (GALT)

Q3 2017 13F Holders as of 30 Sep 2017

Type / Class
Equity / COM NEW
Total 13F shares
3,785,199
Share change
+23,619
Total reported value
$8,075,086
Put/Call ratio
133%
Price per share
$2.13
Number of holders
43
Value change
+$14,345
Number of buys
13
Number of sells
14

Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q3 2017

As of 30 Sep 2017, GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by 43 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,785,199 shares. The largest 10 holders included VANGUARD GROUP INC, D.A. DAVIDSON & CO., Advisor Group, Inc., BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, Benchmark Capital Advisors, SUSQUEHANNA INTERNATIONAL GROUP, LLP, COURAGE CAPITAL MANAGEMENT LLC, US BANCORP \DE\, and Neuberger Berman Group LLC. This page lists 43 institutional shareholders reporting positions in this security for the Q3 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.